Ticking all the boxes

Neuren is ticking all the boxes .
1.Exclusive advanced negotiation with undisclosed pharmaceutical company regarding a potential partnering agreement for the development and commercialisation of trofinetide .
2.Pharmaceutical company invested $5.3 million Aussie at $4.00 a share in Neuren.
3.Estimated net cash inflow this quarter $628,000 as per last quarterly .
4.Lanstead needs to put in aprox $850,000 per month for next 9 months under share sale agreement .
5.Cash at bank $10 million Aussie .
6.Definetely no need for capital raising.
7.First patent for trofinetide granted in Japan on 30 th April 2018.New patents extending to 2032 granted in the USA,Europe and Japan covering trofinetide in Rett syndrome Fragile x syndrome and other autism spectrum disorders .
8.Directors and Management have plenty of skin in the game .
9.Statistically significant and clinically meangful improvement demonstrated in Phase 2 clinical trial in girls with
Rett syndrome aged 5 to 15 .
10.Agreement reached at end of Phase 2 Meeting with FDAon the key elements of Phase 3 program for Rett syndrome.